inclusion criteria: 1. index cases: * provided a signed and dated informed consent form * aged 18 to \<80 years of age * confirmed sars-cov-2 diagnosis by pcr within 72 hours of first treatment dose * the first known diagnosis in the household * not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days * must plan to remain resident in the household during the study * lives in household with at least one other 'treatment-eligible household contact' 2. treatment-eligible household contacts: * provided a signed and dated informed consent form * aged 18 to \<80 years of age, * not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days * must plan to remain resident in the household during the study * no history of previously confirmed sars-cov-2 diagnosis 3. treatment-ineligible household contacts: * provided a signed and dated informed consent form, parental informed consent, and assent if applicable * under 18 years or ≥ 80 years of age or aged 18 to \<80 years with any contraindication for ifn treatment listed in 'exclusion criteria' * not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days * must plan to remain resident in the household during the study * no history of previously confirmed sars-cov-2 diagnosis

inclusion criteria: 1. index cases: * provided a signed and dated informed consent form * aged 18 to \<80 years of age * confirmed sars-cov-2 diagnosis by pcr within 72 hours of first treatment dose * the first known diagnosis in the household * not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days * must plan to remain resident in the household during the study * lives in household with at least one other 'treatment-eligible household contact' 2. treatment-eligible household contacts: * provided a signed and dated informed consent form * aged 18 to \<80 years of age, * not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days * must plan to remain resident in the household during the study * no history of previously confirmed sars-cov-2 diagnosis 3. treatment-ineligible household contacts: * provided a signed and dated informed consent form, parental informed consent, and assent if applicable * under 18 years or ≥ 80 years of age or aged 18 to \<80 years with any contraindication for ifn treatment listed in 'exclusion criteria' * not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days * must plan to remain resident in the household during the study * no history of previously confirmed sars-cov-2 diagnosis

inclusion criteria: index cases: provided a signed and dated informed consent form aged 18 to <80 years of age confirmed sars-cov-2 diagnosis by pcr within 72 hours of first treatment dose the first known diagnosis in the household not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days must plan to remain resident in the household during the study lives in household with at least one other 'treatment-eligible household contact' treatment-eligible household contacts: provided a signed and dated informed consent form aged 18 to <80 years of age, not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days must plan to remain resident in the household during the study no history of previously confirmed sars-cov-2 diagnosis treatment-ineligible household contacts: provided a signed and dated informed consent form, parental informed consent, and assent if applicable under 18 years or ≥ 80 years of age or aged 18 to <80 years with any contraindication for ifn treatment listed in 'exclusion criteria' not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days must plan to remain resident in the household during the study no history of previously confirmed sars-cov-2 diagnosis

inclusion criteria: index cases: provided a signed and dated informed consent form aged 18 to <80 years of age confirmed sars-cov-2 diagnosis by pcr within 72 hours of first treatment dose the first known diagnosis in the household not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days must plan to remain resident in the household during the study lives in household with at least one other 'treatment-eligible household contact' treatment-eligible household contacts: provided a signed and dated informed consent form aged 18 to <80 years of age, not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days must plan to remain resident in the household during the study no history of previously confirmed sars-cov-2 diagnosis treatment-ineligible household contacts: provided a signed and dated informed consent form, parental informed consent, and assent if applicable under 18 years or ≥ 80 years of age or aged 18 to <80 years with any contraindication for ifn treatment listed in 'exclusion criteria' not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days must plan to remain resident in the household during the study no history of previously confirmed sars-cov-2 diagnosis

inclusion criteria: 1. index cases: - provided a signed and dated informed consent form - aged 18 to <80 years of age - confirmed sars-cov-2 diagnosis by pcr within 72 hours of first treatment dose - the first known diagnosis in the household - not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days - must plan to remain resident in the household during the study - lives in household with at least one other 'treatment-eligible household contact' 2. treatment-eligible household contacts: - provided a signed and dated informed consent form - aged 18 to <80 years of age, - not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days - must plan to remain resident in the household during the study - no history of previously confirmed sars-cov-2 diagnosis 3. treatment-ineligible household contacts: - provided a signed and dated informed consent form, parental informed consent, and assent if applicable - under 18 years or ≥ 80 years of age or aged 18 to <80 years with any contraindication for ifn treatment listed in 'exclusion criteria' - not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days - must plan to remain resident in the household during the study - no history of previously confirmed sars-cov-2 diagnosis

inclusion criteria: 1. index cases: - provided a signed and dated informed consent form - aged 18 to <80 years of age - confirmed sars-cov-2 diagnosis by pcr within 72 hours of first treatment dose - the first known diagnosis in the household - not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days - must plan to remain resident in the household during the study - lives in household with at least one other 'treatment-eligible household contact' 2. treatment-eligible household contacts: - provided a signed and dated informed consent form - aged 18 to <80 years of age, - not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days - must plan to remain resident in the household during the study - no history of previously confirmed sars-cov-2 diagnosis 3. treatment-ineligible household contacts: - provided a signed and dated informed consent form, parental informed consent, and assent if applicable - under 18 years or ≥ 80 years of age or aged 18 to <80 years with any contraindication for ifn treatment listed in 'exclusion criteria' - not currently enrolled in a clinical trial and agree to not take any other investigational treatments over the next 28 days - must plan to remain resident in the household during the study - no history of previously confirmed sars-cov-2 diagnosis